Catheter Ablation of Ventricular Fibrillation

Fatima M Ezzeddine; Ashley M Darlington; Christopher V DeSimone; Samuel J Asirvatham

doi:10.1016/j.ccep.2022.06.002

Catheter Ablation of Ventricular Fibrillation

Card Electrophysiol Clin. 2022 Dec;14(4):729-742. doi: 10.1016/j.ccep.2022.06.002. Epub 2022 Oct 28.

Authors

Fatima M Ezzeddine¹, Ashley M Darlington¹, Christopher V DeSimone¹, Samuel J Asirvatham²

Affiliations

¹ Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, USA.
² Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, USA. Electronic address: asirvatham.samuel@mayo.edu.

PMID: 36396189
DOI: 10.1016/j.ccep.2022.06.002

Abstract

Ventricular fibrillation (VF) is a common cause of sudden cardiac death (SCD) and is unfortunately without a cure. Current therapies focus on prevention of SCD, such as implantable cardioverter-defibrillator (ICD) implantation and anti-arrhythmic agents. Significant progress has been made in improving our understanding and ability to target the triggers of VF, via advanced mapping and ablation techniques, as well as with autonomic modulation. However, the critical substrate for VF maintenance remains incompletely defined. In this review, we discuss the evidence behind the basic mechanisms of VF and review the current role of catheter ablation in patients with VF.

Keywords: Autonomic nervous system; Catheter ablation; Purkinje fibers; Ventricular fibrillation.

Publication types

Review

MeSH terms

Anti-Arrhythmia Agents
Catheter Ablation* / methods
Death, Sudden, Cardiac / prevention & control
Humans
Ventricular Fibrillation*

Substances

Anti-Arrhythmia Agents